The estimated Net Worth of Norman Payson is at least $88.2 Milione dollars as of 22 December 2022. Norman Payson owns over 6,617 units of Progyny Inc stock worth over $6,239,013 and over the last 8 years he sold PGNY stock worth over $81,856,944. In addition, he makes $131,445 as Independent Director at Progyny Inc.
Norman has made over 108 trades of the Progyny Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 6,617 units of PGNY stock worth $204,399 on 22 December 2022.
The largest trade he's ever made was selling 568,994 units of Progyny Inc stock on 29 October 2019 worth over $6,953,107. On average, Norman trades about 24,275 units every 10 days since 2016. As of 22 December 2022 he still owns at least 272,446 units of Progyny Inc stock.
You can see the complete history of Norman Payson stock trades at the bottom of the page.
Dr. Norman Payson M.D. serves as Independent Director of the Company. Dr. Payson was co-founder and Chief Executive Officer of Healthsource from 1985 to 1997, Chief Executive Officer of Oxford Health Plans from 1998 to 2002, Chairman of Concentra from 2005 to 2008 and Chief Executive Officer of Apria Healthcare Group Inc. from 2008 to 2012, where he is currently a member of the board of directors. Since 1997, Dr. Payson has served as President and a director of NCP, Inc., his family office, through which he engages in consulting and personal investment activities. Additionally, Dr. Payson has served as a strategic advisor for Evolent Health, Inc., or Evolent, since March 2014 and from December 2013 to June 2019, Dr. Payson also served on the board of directors of Evolent. Dr. Payson is currently serving on the Board of Directors of various private and not-for-profit companies including Access Clinical Partners, City of Hope, Smile Brands, HPM National Advisory Board at the Mailman School of Public Health at Columbia and USC Schaeffer Center Advisory Board. Dr. Payson is also on the board of Kiva Foundation, a private charitable foundation organized by Dr. Payson and his wife in June 1998. Until June 2019, Dr. Payson served as a director at Geisel School of Medicine at Dartmouth, where he now serves as director emeritus. Dr. Payson holds a Bachelor of Science degree in earth and planetary sciences from the Massachusetts Institute of Technology and received his doctorate in medicine from Dartmouth Medical School. Dr. Payson is a California licensed physician. Payson is qualified to serve on our board of directors because of his 30-year career as chief executive officer or chairman of multiple healthcare organizations, including publicly-traded companies.
As the Independent Director of Progyny Inc, the total compensation of Norman Payson at Progyny Inc is $131,445. There are 10 executives at Progyny Inc getting paid more, with David Schlanger having the highest compensation of $4,964,200.
Norman Payson is 72, he's been the Independent Director of Progyny Inc since 2016. There are no older and 16 younger executives at Progyny Inc.
Norman's mailing address filed with the SEC is C/O PROGYNY, INC., 1359 BROADWAY, 2ND FLOOR, NEW YORK, NY, 10018.
Over the last 5 years, insiders at Progyny Inc have traded over $949,717,514 worth of Progyny Inc stock and bought 76,923 units worth $999,999 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Plc Gsk e Gp A, Llcbonderman Davidcou.... On average, Progyny Inc executives and independent directors trade stock every 4 days with the average trade being worth of $2,005,422. The most recent stock trade was executed by Michael E Sturmer on 16 July 2024, trading 9,030 units of PGNY stock currently worth $270,900.
progyny is the leading fertility benefits company that combines service, science, technology and data to provide fertility solutions for self-insured employers. progyny’s approach offers members a comprehensive value based treatment plan that is based on the latest medical science and technology. the benefit plans are designed to improve outcomes, shorten time to pregnancy and reduce total fertility-related costs. progyny supports all fertility solutions to include ivf, iui, embryo banking, egg freezing, adoption and surrogacy.
Progyny Inc executives and other stock owners filed with the SEC include: